Pengfei Cui

833 total citations
34 papers, 599 citations indexed

About

Pengfei Cui is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Pengfei Cui has authored 34 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Pengfei Cui's work include Cancer Immunotherapy and Biomarkers (17 papers), Lung Cancer Treatments and Mutations (10 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Pengfei Cui is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Lung Cancer Treatments and Mutations (10 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Pengfei Cui collaborates with scholars based in China, Ghana and United States. Pengfei Cui's co-authors include Yi Hu, Junxun Ma, Haitao Tao, Ziwei Huang, Zhaozhen Wu, Zhefeng Liu, Di Huang, Shixue Chen, Jinliang Wang and Yuanyu Qian and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Oncogene.

In The Last Decade

Pengfei Cui

32 papers receiving 597 citations

Peers

Countries citing papers authored by Pengfei Cui

Since Specialization

Citations

This map shows the geographic impact of Pengfei Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pengfei Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pengfei Cui more than expected).

Fields of papers citing papers by Pengfei Cui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pengfei Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pengfei Cui. The network helps show where Pengfei Cui may publish in the future.

Co-authorship network of co-authors of Pengfei Cui

This figure shows the co-authorship network connecting the top 25 collaborators of Pengfei Cui. A scholar is included among the top collaborators of Pengfei Cui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pengfei Cui. Pengfei Cui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genome-wide identification and expression profile analysis of TALE superfamily genes under hormone and abiotic stress in maize (Zea may L.) 2025 ·Frontiers in Plant Science ·(unknown), Dongbo Zhao, (unknown), Pengfei Cui, (unknown)	0
2	First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study 2025 ·The Oncologist ·Lijie Wang, (unknown), Ting Wang, Pengfei Cui, Guang‐Ying Chen, Xiao Han, Z. Ma, (unknown), (unknown), Junxun Ma, Fan Zhang, Haitao Tao, Yi Hu	0
3	Preparation and properties of walnut oil microcapsules 2025 ·LWT ·Pengfei Cui, (unknown), Xiao Xiao, (unknown), Siting Li, Chen Zhou, Yingmin Jia, Aijin Ma	2
4	Factors for incidence risk and prognosis of synchronous brain metastases in pulmonary large cell carcinoma patients: a population-based study 2023 ·BMC Pulmonary Medicine ·Xuan Zheng, (unknown), Lijie Wang, Haitao Tao, Di Huang, Ziwei Huang, Xiaoyan Li, Pengfei Cui, Tao Li, Qingyan Liu, Yi Hu	3
5	Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis 2023 ·Oncogene ·Pengfei Cui, Jinfeng Li, Haitao Tao, Xiaoyan Li, Liangliang Wu, Junxun Ma, Huanhuan Wang, Tingting Liu, Min Zhang, (unknown)	6
6	Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field 2022 ·Frontiers in Oncology ·Siyuan Chen, Yu Qiao, Juan Chen, Yanan Li, (unknown), Pengfei Cui, Ziwei Huang, (unknown), Yiming Gao, Yi Hu, Zhefeng Liu	7
7	Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting 2021 ·Cancer Immunology Immunotherapy ·Zhaozhen Wu, Haitao Tao, Sujie Zhang, Xiao Wang, Junxun Ma, Ruixin Li, Zhefeng Liu, Jinliang Wang, Pengfei Cui, Shixue Chen, Di Huang, Ziwei Huang, Xuan Zheng, Yi Hu	10
8	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis 2021 ·Frontiers in Oncology ·Shixue Chen, Zhibo Zhang, Xuan Zheng, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Pengfei Cui, Di Huang, Ziwei Huang, Zhaozhen Wu, Yi Hu	83
9	Predicting disease progression in advanced non-small cell lung cancer with circulating neutrophil-derived and platelet-derived microparticles 2021 ·BMC Cancer ·Tingting Liu, Jiang Wang, Tao Li, Pengfei Cui, (unknown), (unknown), Wei Ge, Sujie Zhang, Hongxia Li, Yi Hu	11
10	Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors 2021 ·Translational Lung Cancer Research ·Shixue Chen, Ruixin Li, Zhibo Zhang, Ziwei Huang, Pengfei Cui, Wangping Jia, Sujie Zhang, Haitao Tao, Lijie Wang, Xiaoyan Li, Jinliang Wang, Junxun Ma, Zhefeng Liu, Di Huang, Xuan Zheng, Yuichi Saito, Yoshinobu Ichiki, Yi Hu	20
11	Alveolar macrophages in patients with non-small cell lung cancer. 2020 ·PubMed Central ·Jinfeng Li, Jin‐Long Li, Lingxiong Wang, (unknown), Liangliang Wu, Haitao Tao, Sujie Zhang, Pengfei Cui, Xiaoyan Li, Xiaoyun Zhang, Zhou Zhou, Shunchang Jiao, Yi Hu	2
12	Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC 2020 ·Scientific Reports ·Pengfei Cui, Ruixin Li, Ziwei Huang, Zhaozhen Wu, Haitao Tao, Sujie Zhang, Yi Hu	33
13	<p>Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors</p> 2020 ·Journal of Hepatocellular Carcinoma ·Shixue Chen, Ziwei Huang, Wangping Jia, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Lijie Wang, Pengfei Cui, Zhibo Zhang, Di Huang, Zhaozhen Wu, Xuan Zheng, Yi Hu	24
14	Antimicrobial Resistance, Virulence Genes, and Biofilm Formation Capacity Among Enterococcus species From Yaks in Aba Tibetan Autonomous Prefecture, China 2020 ·Frontiers in Microbiology ·Pengfei Cui, Feng Lan, Lan Zhang, Juan He, (unknown), (unknown), Cui Li, Xiaodong Zhao, (unknown), Hao Li, Wenjun Yan, (unknown), Xiaolin Luo, Changwei Lei, Hongning Wang, Xin Yang	44
15	Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer 2019 ·Journal of Cancer ·Fan Zhang, Di Huang, Tao Li, Sujie Zhang, Jinliang Wang, Yuzi Zhang, Guoqiang Wang, Zhengyi Zhao, Junxun Ma, Lijie Wang, Danyang Sun, Pengfei Cui, Shangli Cai, Shunchang Jiao, Lei Zhao, Yi Hu	18
16	Ultrasound-assisted preparation of ACE inhibitory peptide from milk protein and establishment of its in-situ real-time infrared monitoring model 2019 ·Ultrasonics Sonochemistry ·Pengfei Cui, Xue Yang, Qiufang Liang, Shanfen Huang, Feng Lü, John Owusu, Xiaofeng Ren, Haile Ma	36
17	Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study 2018 ·Cancer Medicine ·Pengfei Cui, Zhefeng Liu, Guoqiang Wang, Junxun Ma, Yuanyu Qian, Fan Zhang, Chun Han, (unknown), Ye Li, Xuan Zheng, Danyang Sun, Jing Zhang, Shangli Cai, Shunchang Jiao, Yi Hu	90
18	Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort 2018 ·Therapeutics and Clinical Risk Management ·Danyang Sun, Junxun Ma, Jinliang Wang, Fan Zhang, Lijie Wang, Sujie Zhang, Guang‐Ying Chen, Xiaoyan Li, (unknown), Pengfei Cui, Yi Hu	12
19	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis 2017 ·Therapeutics and Clinical Risk Management ·Pengfei Cui, Junxun Ma, Feixue Wang, Jing Zhang, Haitao Tao, Yi Hu	12
20	Three Female Familial Cases of Solid Pseudopapillary Tumors With a Protease Serine 1 Gene Mutation 2012 ·Pancreas ·(unknown), (unknown), Chunyou Wang, Tao Liu, Pengfei Cui, Xiangsheng Li	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact